Cannabis Technologies (CSE:CAN, Stock Forum), a Vancouver-based biopharmaceutical drug discovery and development firm centering on its proprietary Cannabinoid Drug Design Platform, announced today that the company had appointed life science sector veteran, Tarek Mansour Ph.D. to its scientific advisory board.
The stock eased 7% to 56 cents in early trading, Tuesday.
According to the news release, the 26-year veteran in drug discovery and development within the biotechnology and pharmaceutical sector, has expertise in multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain and under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late-stage development.
Dr. Mansour, whose industrial career began in 1989, holds a Ph.D. from the University of Missouri-Columbia, USA and a diploma in Applied Management from McGill University, Canada, where in 1985 he acted as a research associate in the Immunomedicinal Chemistry Chair.
Company president and CEO, Craig Schneider, commented on the appointment, “We are delighted to welcome Dr. Mansour as a scientific advisor to the Company.”
He went on to illustrate, “Dr. Mansour is a distinguished R&D executive with the experience of drug development discovery to commercialization.”
Then he concluded, “His experience and expertise in both biotechnology and pharmaceutical will be instrumental in guiding our strategic initiatives.”
Cannabis Technologies was in the news recently when the company was highlighted by Chris Parry in an article where Stockhouse staff gave their picks of companies that might have a big June.
Currently there are 33.7m outstanding shares with a market cap of $19.2 million.
FULL DISCLOSURE: Cannabis Technologies is a Stockhouse Publishing client.